Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 13/20 | 0.45 |
| ▸ | EDNRA | P25101 | 13/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12095218 | 1.00 | EDNRB (0.45) | EDNRBEDNRACYP1A2LMNATDP1 | |
| SCHEMBL14298973 | 0.85 | EDNRB (0.46) | EDNRBEDNRACYP1A2LMNATDP1 | |
| SCHEMBL14298965 | 0.85 | EDNRB (0.46) | EDNRBEDNRACYP1A2LMNATDP1 | |
| SCHEMBL7825117 | 0.85 | EDNRB (0.52) | EDNRBEDNRALMNATDP1KDM4E | |
| SCHEMBL14325441 | 0.85 | EDNRB (0.52) | EDNRBEDNRALMNATDP1KDM4E | |
| SCHEMBL9369928 | 0.84 | EDNRB (0.46) | EDNRBEDNRACYP1A2 | |
| SCHEMBL12095201 | 0.83 | EDNRB (0.47) | EDNRBEDNRACYP1A2LMNATDP1 | |
| SCHEMBL18531826 | 0.83 | EDNRB (0.47) | EDNRBEDNRACYP1A2LMNATDP1 | |
| SCHEMBL18531915 | 0.83 | EDNRB (0.47) | EDNRBEDNRACYP1A2LMNATDP1 | |
| SCHEMBL12095293 | 0.83 | EDNRB (0.42) | EDNRBEDNRACYP1A2LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573907-B2 | 2, 4-pyrimidine derivatives and use thereof | SNU R&DB FOUNDATION (KR) | 2017-02-21 | — | — | US | claimed |
| US-20120322802-A1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-20 | — | — | US | claimed |
| EP-2497768-A2 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | SNU R&DB Foundation (KR) | 2012-09-12 | — | — | EP | claimed |
| US-9573907-B2 | 2, 4-pyrimidine derivatives and use thereof | SNU R&DB FOUNDATION (KR) | 2017-02-21 | — | — | US | disclosed |
| US-9573907-B2 | 2, 4-pyrimidine derivatives and use thereof | SNU R&DB FOUNDATION (KR) | 2017-02-21 | — | — | US | disclosed |
| EP-2497768-B1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | SNU R&DB FOUNDATION (KR) | 2016-04-20 | — | — | EP | disclosed |
| US-20120322802-A1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-20 | — | — | US | disclosed |
| US-20120322802-A1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-20 | — | — | US | disclosed |
| EP-2497768-A2 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | SNU R&DB Foundation (KR) | 2012-09-12 | — | — | EP | disclosed |
| EP-0802193-B1 | Process for the preparation of substituted pyrimidines | LONZA AG (CH) | 2001-10-17 | — | — | EP | disclosed |
| US-5840892-A | Process for the preparation of substituted pyrimidines | LONZA AG (CH) | 1998-11-24 | — | — | US | disclosed |
| EP-0802193-A1 | Process for the preparation of substituted pyrimidines | LONZA AG (CH) | 1997-10-22 | — | — | EP | disclosed |
| EP-0562510-A1 | Optically active pyrimidinyl- or triazinyl-oxy-(or -thio)-carbonic acid derivatives, processes for their production and their use as herbicides or plant growth regulators | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322802-A1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | LY96, AIMP1, NLRP1 | EDNRB 4586/4885EDNRA 4633/4885CYP1A2 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.